Friday, 18 Aug 2017

You are here

Non-Prescribed Opioid Abuse by Young Adults

Journal of Addiction Medicine reported that young adults often are "self-medicated" to manage pain.

A study by Marshall et al shows that young men are particularly at risk. They studied 199 young adult non-medical prescription opioid (NMPO) users and found 85% had a former injury or health condition that lead to severe pain and NMPO use. About one-fourth of males and one-third of females said that a health professional had denied them medication to treat severe pain. Many did not have health insurance.

NMPO use was higher in young males, especially white. For women, older age and non-medical use of benzodiazepines -- a class of sedative drugs -- were risk factors for frequent NMPO use.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

No Evidence to Support Use of Gabapentinoids in Low Back Pain

Management of chronic low back pain (CLBP) is often complex, requiring multiple modalities and meds to control pain. An analysis of studies shows that Gabapentinoids, including pregabalin and gabapentin, have little to no benefits but significant risk of adverse effects.  (Citation source https://buff.ly/2warMSU)

Marijuana Has Little Effect on Most Types of Pain

Cannabis has become a regulated product, and many states have made it available with the intent of treating a variety of medical disorders, including chronic pain. A metanalysis published in Annals of Internal Medicine has shown that while cannabis may help neuropathic pain, it is not proven to benefit other types of chronic pain.

One-Third of Americans Took Opioids in 2015

 In the wake of the well-publicized "opioid epidemic", researchers report in the Annals of Internal Medicine (online July 31) that more than one third of U.S. adults were prescribed opioids in 2015 and that misuse remains a major problem. (Citation source http://buff.ly/2vkd8au)

FDA Requests Removal of OPANA-ER from the Market

The U.S. Food and Drug Administration has asked Endo International to withdraw Opana ER from the market, stating that benefits no longer outweigh its risks of this long-acting opioid.

A March 2017 advisory committee concluded that Opana ER, is not safe, and many have called for its removal.

Opana ER is twice as potent as oxycodone and has a high abuse potential when crushed and taken for a massive high effect by addicts.  

Ohio Sues Five Pharma Companies Over Opioid Epidemic

Ohio is suing five major drug manufacturers, accusing them of misrepresenting the risks of prescription opioid painkillers that has resulted in the current opioid epidemic. The Attorney General of Ohio, Mike DeWine, wants to hold big Pharma responsible for a deadly and costly opioid crisis.